These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17509368)

  • 21. [Rising Prostate Specific Antigen following treatment with curative intention].
    Jakobsen H; Pedersen KV
    Ugeskr Laeger; 2007 May; 169(20):1907-9. PubMed ID: 17553369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Salvage prostate brachytherapy for localized prostate cancer failure after external beam radiation therapy.
    Lee HK; Adams MT; Motta J
    Brachytherapy; 2008; 7(1):17-21. PubMed ID: 18201939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.
    Choueiri TK; Dreicer R; Paciorek A; Carroll PR; Konety B
    J Urol; 2008 Mar; 179(3):906-10; discussion 910. PubMed ID: 18207194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship of biochemical outcome to percentage of positive biopsies in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy.
    Guzzo TJ; Levin BM; Lee R; Guo M; Chen Z; Whittington R; Tomaszewski J; Malkowicz SB
    Urology; 2008 Apr; 71(4):723-7. PubMed ID: 18387401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Yuen JS
    J Urol; 2004 Mar; 171(3):1246. PubMed ID: 14767320
    [No Abstract]   [Full Text] [Related]  

  • 26. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.
    Stock RG; Klein TJ; Cesaretti JA; Stone NN
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):753-8. PubMed ID: 19084351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer.
    Morris WJ; Keyes M; Palma D; Spadinger I; McKenzie MR; Agranovich A; Pickles T; Liu M; Kwan W; Wu J; Berthelet E; Pai H
    Urology; 2009 Apr; 73(4):860-5; discussion 865-7. PubMed ID: 19168203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re: B.J. De Castro and K. C. Baker: Effect of flexible cystoscopy on serum prostate-specific antigen values (Urology 2009; 73:237-240).
    Romics I
    Urology; 2009 Jul; 74(1):234. PubMed ID: 19567303
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
    Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
    J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [T1-T2 prostate cancer: treatment by radiation therapy].
    Lagrange JL; Guerif S
    Bull Cancer; 2007 Jul; 94(7 Suppl):F5-14. PubMed ID: 17845988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
    Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brachytherapy doses for prostate cancer customized to risk factors: is it more important "how much" or "where"? In regard to Stone et al. (Int J Radiat Oncol Biol Phys 2007;69:1472-1477).
    Oton CA; Oton F
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):962; author reply 962-3. PubMed ID: 18514795
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: A multi-institutional evaluation of active surveillance for low risk prostate cancer. S. E. Eggener, A. Mueller, R. K. Berglund, R. Ayyathurai, C. Soloway, M. S. Soloway, R. Abouassaly, E. A. Klein, S. J. Jones, C. Zappavigna, L. Goldenberg, P. T. Scardino, J. A. Eastham and B. Guillonneau J Urol 2009; 181: 1635-1641.
    Ayres BE; Bott SR; Barber NJ; Langley SE; Montgomery BS
    J Urol; 2010 Sep; 184(3):1223-4; author reply 1224. PubMed ID: 20655069
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT.
    Pe ML; Trabulsi EJ; Kedika R; Pequignot E; Dicker AP; Gomella LG; Valicenti RK
    Urology; 2009 Jun; 73(6):1328-34. PubMed ID: 19376564
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate-specific antigen testing for the early detection of prostate cancer.
    Kirby R; Fitzpatrick J
    BJU Int; 2004 Nov; 94(7):966-7. PubMed ID: 15541108
    [No Abstract]   [Full Text] [Related]  

  • 37. Re: Correction of prostate-specific antigen velocity for variation may improve prediction of cancer following prostate repeat biopsy.
    Singh A
    Can J Urol; 2009 Jun; 16(3):4659. PubMed ID: 19497173
    [No Abstract]   [Full Text] [Related]  

  • 38. Re: The 20-core prostate biopsy protocol--a new gold standard?: V. Ravery, S. Dominique, X. Panhard, M. Toublanc, L. Boccon-Gibod and L. Boccon-Gibod. J Urol 2008; 179: 504-507.
    Serefoglu EC; Ozdemir AT; Balbay MD
    J Urol; 2008 Nov; 180(5):2256-7. PubMed ID: 18804806
    [No Abstract]   [Full Text] [Related]  

  • 39. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: biopsy and PSA outcome.
    Bachand F; Martin AG; Beaulieu L; Harel F; Vigneault E
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):679-84. PubMed ID: 18963537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upcoming evidences on prostate-specific antigen-based screening for men at risk of prostate cancer.
    Boscolo-Berto R
    Int J Urol; 2009 Sep; 16(9):711. PubMed ID: 19769655
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.